Photo coming soon
Retatrutide
Shipping and payment
Chemistry & specifications
Reference data from public databases. For research use only.
| CAS Number | 2381089-83-2 |
|---|---|
| Molecular Formula | C221H342N46O68 |
| Molecular Weight | 4731 g/mol |
| Residue Count | 39 |
| Sequence (1-letter) | YXQGTFTSDYSIXLDKKAQXAFIEYLLEGGPSSGAPPPS |
| PubChem CID | 171390338 → |
Peer-reviewed research
Every research claim on this page traces to one of the 4 publications below.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 TrialN Engl J Med (2023)View publication →
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trialNat Med (2024)View publication →
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trialLancet Diabetes Endocrinol (2025)View publication →
- Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trialLancet (2026)View publication →